Cargando…
Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?
Currently, one of the leading treatments for non-small-cell lung cancer is immunotherapy involving immune checkpoint inhibitors. These monoclonal antibodies restore the anti-tumour immune response altered by negative immune checkpoint interactions. The most commonly used immunotherapeutics in monoth...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950480/ https://www.ncbi.nlm.nih.gov/pubmed/35328510 http://dx.doi.org/10.3390/ijms23063087 |
_version_ | 1784675150947418112 |
---|---|
author | Krzyżanowska, Natalia Wojas-Krawczyk, Kamila Milanowski, Janusz Krawczyk, Paweł |
author_facet | Krzyżanowska, Natalia Wojas-Krawczyk, Kamila Milanowski, Janusz Krawczyk, Paweł |
author_sort | Krzyżanowska, Natalia |
collection | PubMed |
description | Currently, one of the leading treatments for non-small-cell lung cancer is immunotherapy involving immune checkpoint inhibitors. These monoclonal antibodies restore the anti-tumour immune response altered by negative immune checkpoint interactions. The most commonly used immunotherapeutics in monotherapy are anti-PD-1 and anti-PD-L1 antibodies. The effectiveness of both groups of antibodies has been proven in many clinical trials, which have translated into positive immunotherapeutic registrations for cancer patients worldwide. These antibodies are generally well tolerated, and certain patients achieve durable responses. However, given the resistance of some patients to this form of therapy, along with its other drawbacks, such as adverse events, alternatives are constantly being sought. Specifically, new drugs targeting already known molecules are being tested, and new potential targets are being explored. The aim of this paper is to provide an overview of the latest developments in this area. |
format | Online Article Text |
id | pubmed-8950480 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89504802022-03-26 Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules? Krzyżanowska, Natalia Wojas-Krawczyk, Kamila Milanowski, Janusz Krawczyk, Paweł Int J Mol Sci Review Currently, one of the leading treatments for non-small-cell lung cancer is immunotherapy involving immune checkpoint inhibitors. These monoclonal antibodies restore the anti-tumour immune response altered by negative immune checkpoint interactions. The most commonly used immunotherapeutics in monotherapy are anti-PD-1 and anti-PD-L1 antibodies. The effectiveness of both groups of antibodies has been proven in many clinical trials, which have translated into positive immunotherapeutic registrations for cancer patients worldwide. These antibodies are generally well tolerated, and certain patients achieve durable responses. However, given the resistance of some patients to this form of therapy, along with its other drawbacks, such as adverse events, alternatives are constantly being sought. Specifically, new drugs targeting already known molecules are being tested, and new potential targets are being explored. The aim of this paper is to provide an overview of the latest developments in this area. MDPI 2022-03-13 /pmc/articles/PMC8950480/ /pubmed/35328510 http://dx.doi.org/10.3390/ijms23063087 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Krzyżanowska, Natalia Wojas-Krawczyk, Kamila Milanowski, Janusz Krawczyk, Paweł Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules? |
title | Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules? |
title_full | Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules? |
title_fullStr | Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules? |
title_full_unstemmed | Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules? |
title_short | Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules? |
title_sort | future prospects of immunotherapy in non-small-cell lung cancer patients: is there hope in other immune checkpoints targeting molecules? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950480/ https://www.ncbi.nlm.nih.gov/pubmed/35328510 http://dx.doi.org/10.3390/ijms23063087 |
work_keys_str_mv | AT krzyzanowskanatalia futureprospectsofimmunotherapyinnonsmallcelllungcancerpatientsistherehopeinotherimmunecheckpointstargetingmolecules AT wojaskrawczykkamila futureprospectsofimmunotherapyinnonsmallcelllungcancerpatientsistherehopeinotherimmunecheckpointstargetingmolecules AT milanowskijanusz futureprospectsofimmunotherapyinnonsmallcelllungcancerpatientsistherehopeinotherimmunecheckpointstargetingmolecules AT krawczykpaweł futureprospectsofimmunotherapyinnonsmallcelllungcancerpatientsistherehopeinotherimmunecheckpointstargetingmolecules |